Pharma outlook 2030: From evolution to revolution

January 7, 2019

The pharmaceutical sector is at a crossroads. In a heavily disrupted marketplace, characterized by shifting payer attitudes and patient empowerment, neither incremental adjustments nor steady evolution are likely to halt the decline of the traditional pharmaceutical business model. This paper looks ahead to a 2030 scenario to examine the trends revolutionizing the sector; trends that we expect to have dramatic impacts.

Spotlight

Pharma Services Network

Since 2003, Pharma Services Network has been helping pharmaceutical, biotech, and device sponsors from around the world to identify, qualify, and engage with service providers ideally suited to their needs. We have in-depth knowledge of Internationally based CROs, Regulatory Consultants, and a host of other strategic service providers.

OTHER WHITEPAPERS
news image

Coronavirus (COVID-19) and Its Effect on Pharmaceutical Marketing and Sales

whitePaper | March 16, 2020

With the rapid onset of coronavirus in the United States, many pharma companies are being forced to prepare for a scenario in which their reps cannot visit providers and patients are limited in their ability to visit their healthcare professionals (HCP). The CDC has gone as far as recommending the use of telemedicine and patient portals as primary channels for HCPs and patients to interact.

Read More
news image

The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

whitePaper | April 16, 2020

Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing unexpected cost increases for payers and consumers, and spurring an investigation by the United States Congress. High generic drug prices have had an adverse effect on almost everyone in the pharmaceutical supply chain. Consumers face higher co-pays and prices and health plans are dealing with higher drug spend. Physicians are finding the need to prescribe alternative drug therapies while dealing with angry patients.

Read More
news image

Transforming Patient Journey in Clinical Trials

whitePaper | April 7, 2022

Year after year, the Life Sciences industry expands at a breakneck pace, with pharmaceutical development leading the way.

Read More
news image

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More
news image

How IPD Can Deliver for Life Sciences

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Read More
news image

Paving the way for pharma R&D to use FAIR data

whitePaper | December 16, 2019

The use of FAIR (Findable, Accessible, Interoperable and Reusable) data in drug discovery and development could be transformational. But the pharma industry has been slow to embrace FAIR data — partially because of difficulties in establishing the necessary infrastructure and because of internal culture.

Read More

Spotlight

Pharma Services Network

Since 2003, Pharma Services Network has been helping pharmaceutical, biotech, and device sponsors from around the world to identify, qualify, and engage with service providers ideally suited to their needs. We have in-depth knowledge of Internationally based CROs, Regulatory Consultants, and a host of other strategic service providers.

Events